Baird Financial Group Inc. Takes $429,000 Position in Altimmune, Inc. (NASDAQ:ALT)

Baird Financial Group Inc. bought a new position in Altimmune, Inc. (NASDAQ:ALT - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 59,440 shares of the company's stock, valued at approximately $429,000. Baird Financial Group Inc. owned about 0.08% of Altimmune as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in the stock. SBI Securities Co. Ltd. acquired a new stake in shares of Altimmune in the fourth quarter worth $45,000. Virtus ETF Advisers LLC bought a new position in Altimmune during the fourth quarter valued at about $60,000. Cullen Frost Bankers Inc. bought a new stake in shares of Altimmune in the 4th quarter worth approximately $72,000. 180 Wealth Advisors LLC acquired a new stake in shares of Altimmune during the 4th quarter worth approximately $78,000. Finally, KLP Kapitalforvaltning AS bought a new stake in shares of Altimmune during the fourth quarter valued at approximately $81,000. Institutional investors own 78.05% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on ALT. HC Wainwright restated a "buy" rating and issued a $12.00 price objective on shares of Altimmune in a research note on Thursday, April 3rd. William Blair restated a "market perform" rating on shares of Altimmune in a research note on Friday, March 14th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Altimmune presently has a consensus rating of "Buy" and an average price target of $20.20.

Altimmune Stock Performance

Shares of NASDAQ ALT traded down $0.08 during mid-day trading on Monday, hitting $5.50. 1,496,447 shares of the stock were exchanged, compared to its average volume of 2,823,171. Altimmune, Inc. has a twelve month low of $3.55 and a twelve month high of $11.16. The stock's fifty day simple moving average is $5.11 and its two-hundred day simple moving average is $6.56. The company has a market cap of $446.09 million, a P/E ratio of -3.55 and a beta of 1.13.

Altimmune (NASDAQ:ALT - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.09. The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.00 million. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. During the same quarter in the previous year, the company posted ($0.34) EPS. As a group, equities research analysts predict that Altimmune, Inc. will post -1.35 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CFO Gregory L. Weaver purchased 10,000 shares of the firm's stock in a transaction that occurred on Thursday, March 13th. The shares were acquired at an average price of $5.20 per share, for a total transaction of $52,000.00. Following the completion of the acquisition, the chief financial officer now directly owns 10,000 shares in the company, valued at approximately $52,000. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 4.10% of the stock is owned by corporate insiders.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.